Virtus ETF Advisers’s Aligos Therapeutics ALGS Stock Holding History

Virtus ETF Advisers’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-537	Closed	-$29K	–	439
2022 Q1	$29K	Sell	537 -31	-5%	-$2.48K	0.01%	370
2021 Q4	$169K	Buy	568 +295	+108%	+$108K	0.06%	289
2021 Q3	$106K	Sell	273 -14	-5%	-$5.54K	0.05%	378
2021 Q2	$146K	Buy	+287	New	+$183K	0.06%	393

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Virtus ETF Advisers's ALGS Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 537 shares — an estimated $29K sold.

Virtus ETF Advisers first reported a position in ALGS in Q2 2021 and held it in 4 quarters. The position peaked at $169K in Q4 2021. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

Virtus ETF Advisers reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 537 Aligos Therapeutics shares in Q2 2022, an estimated $29K.
Virtus ETF Advisers first reported a position in Aligos Therapeutics in Q2 2021 and held it in 4 quarters.
Virtus ETF Advisers's Aligos Therapeutics position peaked at $169K in Q4 2021.
59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.